Drugs / AZD0424
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01668550 | Oct 2012 → May 2016 | cancer | Cancer Research UK | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0424 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01668550 ↗ |
| Action | Inhibit | “inhibitor of Src and ABL1 kinases” NCT01668550 ↗ |
| Modality | Small molecule | — CHEMBL5314408 ↗ |
| Route | Oral | “administered as a flat dose orally once a day” NCT01668550 ↗ |
| Target | ABL1 | “inhibitor of Src and ABL1 kinases” NCT01668550 ↗ |
| Target | SRC | “inhibitor of Src and ABL1 kinases” NCT01668550 ↗ |